Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)
Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)
To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
Inclusion Criteria:
Exclusion Criteria:
Buenos Aires, Buenos Aires B1842DID, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires C1425DES, Argentina
Derqui Pilar - Buenos Aires, B1629ODT, Argentina
Kaohsiung Hsien, 833, Taiwan
Puzih City, 61363, Taiwan
Muang, 40002, Thailand